Print

Date Printed: October 17, 2017: 04:12 PM

Private Property of Blue Cross and Blue Shield of Florida.
This medical policy (medical coverage guideline) is Copyright 2017, Blue Cross and Blue Shield of Florida (BCBSF). All Rights Reserved. You may not copy or use this document or disclose its contents without the express written permission of BCBSF. The medical codes referenced in this document may be proprietary and owned by others. BCBSF makes no claim of ownership of such codes. Our use of such codes in this document is for explanation and guidance and should not be construed as a license for their use by you. Before utilizing the codes, please be sure that to the extent required, you have secured any appropriate licenses for such use. Current Procedural Terminology (CPT) is copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use. CPT® is a trademark of the American Medical Association. The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

09-J2000-49

Original Effective Date: 03/15/16

Reviewed: 06/14/17

Revised: 09/15/17

Next Review: 06/13/18

Subject: Daratumumab (Darzalex®) Injection

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

           
Dosage/ Administration Position Statement Billing/Coding Reimbursement Program Exceptions Definitions
           
Related Guidelines Other References Updates   Previous Version
           

DESCRIPTION:

Daratumumab (Darzalex®) is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody that binds to CD38, a transmembrane glycoprotein expressed on the surface of many hematopoietic cells, and causes lysis of multiple myeloma cells. It was first approved by the FDA in November 2015 for the treatment of patients with multiple myeloma (MM) who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. Daratumumab was previously granted orphan drug designation for the treatment of MM in May 2013. The indication for use was expanded in November 2016 for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. In June 2017, the FDA-approved indication was expanded again to include use, in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with MM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Daratumumab also has orphan drug designations for the treatment of follicular or mantle cell lymphoma (August 2015) and diffuse large B-cell lymphoma (November 2015).

The safety and efficacy of daratumumab, leading to FDA-approval, were assessed in an open-label, multicenter, phase 2, single-arm study (n=106). An overall response rate (ORR) of 29.2% (n=31) was achieved with daratumumab monotherapy in patients with relapsed or refractory MM. Patients had received at least three prior therapies including a PI and an immunomodulatory agent or were double-refractory to a PI and an immunomodulatory agent. A stringent complete response was reported in 2.8% (n=3), complete response (CR) in 0%, very good partial response (VGPR) in 9.4% (n=10), and partial response in 17% (n=18). The median time to response was 1 month, and median duration of response was 7.4 months. In this study, patients had received a median of five prior therapies, 97% of patients had refractory disease to the last therapy, and 80% of patients had received an autologous stem cell transplantation (ASCT). Prior therapies included bortezomib (99%), lenalidomide (99%), pomalidomide (63%) and carfilzomib (50%).

The National Comprehensive Cancer Network (NCCN) Guidelines for MM (Version 3.2017) list two daratumumab triplet drug therapies (daratumumab + bortezomib + dexamethasone, and daratumumab + lenalidomide + dexamethasone) as category 1 preferred regimens for the treatment of previously treated MM. There are numerous other category 1 preferred regimens listed by NCCN. The triplet regimen with bortezomib is supported by an open-label, phase III trial (n=498) in which subjects were randomized to receive daratumumab + bortezomib + dexamethasone triplet therapy, or bortezomib + dexamethasone doublet therapy. Subjects were excluded if there was previous evidence of refractoriness or intolerance to bortezomib or another PI, like ixazomib and carfilzomib. The ORR was 82.9% with triplet therapy vs. 63.2% with doublet therapy (p<0.001). The rates of VGPR and CR were doubled with triplet vs. doublet therapy (59.2% vs. 29.1%, p<0.001, and 19.2% vs. 9%, p<0.001, respectively). Adverse effects were more common with triplet therapy with grade 3 or 4 thrombocytopenia and neutropenia occurring more frequently (45.3% vs. 32.9%, and 12.8% vs. 4.2%, respectively). The triplet regimen with lenalidomide is supported by a phase III trial (n=569) in which subjects were randomized to receive daratumumab + lenalidomide + dexamethasone triplet therapy, or lenalidomide + dexamethasone doublet therapy. Subjects were excluded if there was previous evidence of refractoriness or intolerance to lenalidomide. The ORR was 92.9% with triplet therapy vs. 76.4% with doublet therapy (p<0.001). The CR was more than doubled with triplet vs. doublet therapy (43.1% vs. 19.2%, p<0.001). Grade 3 or 4 neutropenia occurred more frequently with triplet therapy (51.9% vs. 37%) and daratumumab-associated infusion-related reactions occurred in 47.7% of patients.

Daratumumab monotherapy is listed as a category 2A preferred regimen for the treatment of previously treated MM with a footnote stating that the regimen is indicated for patients who have received at least three prior therapies, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and an immunomodulatory agent for relapse or for progressive or refractory disease.

POSITION STATEMENT:

Initiation of daratumumab (Darzalex) meets the definition of medical necessity when ALL of the following criteria are met (“1”, “2”, “3”, “4”, “5”, and “6”):

1. The member has a diagnosis of relapsed or refractory multiple myeloma (MM)

2. The member has previously received at least ONE prior line of therapy for their MM

3. ANY of the following (“a”, b”, “c”, or “d”):

a. Daratumumab will be used as monotherapy for treatment of the member’s MM

b. BOTH of the following (“i” and “ii”):

i. Daratumumab will be used as triplet therapy in combination with both bortezomib (Velcade) and dexamethasone for treatment of the member’s MM

ii. The member’s MM was not previously refractory (i.e., disease progression on treatment or progression within 60 days after the last dose of a given therapy) to a proteasome inhibitor-containing treatment regimen (e.g., bortezomib, carfilzomib, ixazomib)

c. BOTH of the following (“i” and “ii”):

i. Daratumumab will be used as triplet therapy in combination with both lenalidomide (Revlimid) and dexamethasone for treatment of the member’s MM

ii. The member’s MM was not previously refractory (i.e., disease progression on treatment or progression within 60 days after the last dose of a given therapy) to a lenalidomide-containing treatment regimen [disease progression during low-dose lenalidomide maintenance treatment (e.g., 10 mg) is not considered refractory to lenalidomide for purposes of this requirement]

d. ALL of the following (“i”, “ii”, and “iii”):

i. Daratumumab will be used as triplet therapy in combination with both pomalidomide (Pomalyst) and dexamethasone for treatment of the member’s MM

ii. The member has received at least two prior therapies for their MM that include lenalidomide and a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib)

iii. The member’s MM was not previously refractory (i.e., disease progression on treatment or progression within 60 days after the last dose of a given therapy) to a pomalidomide-containing regimen

4. The member’s MM was not previously refractory (i.e., disease progression on treatment or progression within 60 days after the last dose of a given therapy) to a daratumumab-containing treatment regimen

5. The dosage of daratumumab does not exceed 16 mg/kg given more often than the following:

a. If used as monotherapy:

i. Weeks 1 to 8: Weekly for 8 doses

ii. Weeks 9 to 24: Every two weeks for 8 doses

iii. Week 25 onwards until disease progression: Every four weeks

b. If used as triplet therapy with bortezomib and dexamethasone (one cycle is 21 days):

i. Cycles 1 to 3 (weeks 1 to 9): Weekly (i.e., days 1, 8, and 15 of each cycle) for 9 doses

ii. Cycles 4 to 9 (weeks 10 to 24): Every 3 weeks (i.e., day 1 of each cycle) for 5 doses

iii. After cycle 9 (week 25): Every 4 weeks

c. If used as triplet therapy with lenalidomide or pomalidomide and dexamethasone (one cycle is 28 days):

i. Cycles 1 to 2 (weeks 1 to 8): Weekly (i.e., day 1, 8, 15, and 22 of each cycle) for 8 doses

ii. Cycles 3 to 6 (weeks 9 to 24): Every 2 weeks (i.e., day 1 and 15 of each cycle) for 8 doses

iii. Cycle 7 and beyond (week 25): Every 4 weeks (i.e., day 1 of each cycle)

6. Laboratory documentation of the member’s baseline (i.e., within 60 days prior to initiating treatment with daratumumab) serum monoclonal protein (M-protein) as detected by serum protein electrophoresis (SPEP) is provided*

*If the M-protein is undetectable by SPEP, documentation of a baseline serum free light chain assay (SFLCA) must also be provided

Approval duration: 6 months

Continuation of daratumumab (Darzalex) meets the definition of medical necessity when ALL of the following criteria are met:

1. An authorization or reauthorization for daratumumab has been previously approved by Florida Blue or another health plan in the past 2 years for the treatment of multiple myeloma, OR the member previously met ALL indication-specific initiation criteria

2. Daratumumab is being used in ANY of following regimens (“a”, “b”, “c”, or “d”):

a. Triplet therapy in combination with both bortezomib and dexamethasone

b. Triplet therapy in combination with both lenalidomide and dexamethasone

c. Triplet therapy in combination with both pomalidomide and dexamethasone

d. Monotherapy

3. The member’s dosage of daratumumab does not exceed 16 mg/kg given more often than the following:

a. If used as monotherapy:

i. Weeks 1 to 8: Weekly for 8 doses

ii. Weeks 9 to 24: Every two weeks for 8 doses

iii. Week 25 onwards until disease progression: Every four weeks

b. If used as triplet therapy with bortezomib and dexamethasone (one cycle is 21 days):

i. Cycles 1 to 3 (weeks 1 to 9): Weekly (i.e., days 1, 8, and 15 of each cycle) for 9 doses

ii. Cycles 4 to 9 (weeks 10 to 24): Every 3 weeks (i.e., day 1 of each cycle) for 5 doses

iii. After cycle 9 (week 25): Every 4 weeks

c. If used as triplet therapy with lenalidomide or pomalidomide and dexamethasone (one cycle is 28 days):

i. Cycles 1 to 2 (weeks 1 to 8): Weekly (i.e., day 1, 8, 15, and 22 of each cycle) for 8 doses

ii. Cycles 3 to 6 (weeks 9 to 24): Every 2 weeks (i.e., day 1 and 15 of each cycle) for 8 doses

iii. Cycle 7 and beyond (week 25): Every 4 weeks (i.e., day 1 of each cycle)

4. Member meets EITHER of the following (“a” or “b”):

a. If less than 18 months of treatment - a serum M-protein value decrease of 25% or more* compared to baseline, or M-protein is undetectable; AND no increase in the size or number of lytic bone lesions after at least two cycles of treatment with daratumumab – laboratory documentation of the follow-up serum-M protein must be submitted†,#

b. 18 months or more of treatment - provider attestation that the member has not had disease progression during daratumumab treatment

*If the M-protein was undetectable by SPEP at baseline and a baseline SFLCA is available, a decrease of 25% or more in the difference between the light chain produced by the myeloma cells (lambda or kappa) and the other light chain must be achieved

If the M-protein was undetectable by SPEP at baseline and a baseline SFLCA is available, laboratory documentation of a follow-up SFLCA must be submitted

#An exception is permitted if a baseline M-protein AND SFLCA are unavailable. In these cases the physician may provide an attestation of a beneficial clinical response which must include no increase in the size or number of lytic bone lesions.

Approval duration: 1 year

Daratumumab (Darzalex) meets the definition of medical necessity when used to treat the following orphan indications AND associated criteria are met:

1. Member has a diagnosis of any of the following:

a. Diffuse large B-cell lymphoma

b. Follicular lymphoma

c. Mantle cell lymphoma

2. Member has received at least one prior therapy for treatment of their disease

3. The dosage of daratumumab does not exceed 16 mg/kg given more often than the following:

a. Weeks 1 to 8: Weekly

b. Weeks 9 to 24: Every two weeks

c. Week 25 onwards until disease progression: Every four weeks

Approval duration: 1 year

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER’S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

FDA-Approved

• In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy

In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

As monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

• Monotherapy, and combination therapy with lenalidomide or pomalidomide and low-dose dexamethasone (4-week cycle regimen)

o The recommended dose is 16 mg/kg actual body weight administered as an IV infusion (after dilution) according to the following dosing schedule:

- Weeks 1 to 8: Weekly (total of 8 doses)

- Weeks 9 to 24: Every two weeks (total of 8 doses)

- Week 25 onwards until disease progression: Every four weeks

• Combination therapy with bortezomib and dexamethasone (3-week cycle regimen)

o The recommended dose is 16 mg/kg actual body weight administered as an IV infusion (after dilution) according to the following dosing schedule:

- Weeks 1 to 9: Weekly (total of 9 doses)

- Weeks 10 to 24: Every three weeks (total of 5 doses)

- Week 25 onwards until disease progression: Every four weeks

• The initial infusion rate is 50 mL/hr with a maximum rate of 200 mL/hr. Only increase the rate in the absence of infusion reactions with the previous infusion. See the package insert for more detailed recommendations.

• Administer with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.22 or 0.2 micrometer).

• Pre-medicate patients with a corticosteroid, oral acetaminophen, and oral or IV antihistamine one hour prior to every infusion.

• For monotherapy, post-medicate patients with an oral corticosteroid on the first and second day after all infusions. For combination therapy, consider administering low-dose oral methylprednisolone (≤20 mg) or equivalent, the day after the infusion. However, if a background regimen-specific corticosteroid (e.g. dexamethasone) is administered the day after the infusion, additional post-infusion medications may not be needed.

• Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting daratumumab and continue for 3 months following treatment.

Dose Adjustments

• Dosage adjustments are not recommended for adverse reactions. Adverse reactions are addressed with treatment interruption and slower infusion rates.

• Renal impairment: no dosage adjustment is necessary for patients with pre-existing renal impairment.

• Hepatic impairment: no dosage adjustments are necessary for patients with mild hepatic impairment (Total Bilirubin [TB] 1× to 1.5× upper limit of normal [ULN] or aspartate aminotransferase [AST] >ULN). Daratumumab has not been studied in patients with moderate to severe hepatic impairment (TB >1.5× ULN and any AST).

Drug Availability

• 100 mg/5 mL and 400 mg/20 mL solution for injection

PRECAUTIONS:

Boxed Warnings

• None

Contraindications

• None

Precautions/Warnings

• Infusion Reactions: Daratumumab can cause severe infusion reactions (e.g., bronchospasm, hypoxia, dyspnea, and hypertension). Approximately half of all patients experienced a reaction, most during the first infusion. Interrupt the infusion for infusion reactions of ANY severity. Permanently discontinue the infusion in case of life-threatening infusion reactions (Grade 4). For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion.

• Interference with Serological Testing: Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Type and screen patients prior to starting treatment. Inform blood banks that a patient has received daratumumab.

• Interference with Determination of Complete Response: daratumumab is a human IgG kappa monoclonal antibody that can be detected on both, the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.

• Pregnancy: There are no human data to inform a risk with use of daratumumab during pregnancy. Animal studies have not been conducted Immunoglobulin G1 (IgG1) monoclonal antibodies are transferred across the placenta. Based on its mechanism of action, daratumumab may cause fetal myeloid or lymphoid-cell depletion and decreased bone density.

BILLING/CODING INFORMATION:

The following codes may be used to describe:

HCPCS Coding

J9145

Injection, daratumumab, 10 mg

ICD-10 Diagnoses Codes That Support Medical Necessity

C82.00 – C82.99

Follicular lymphoma

C83.10 – C83.19

Mantle Cell lymphoma

C83.30 – C83.39

Diffuse large B-cell lymphoma

C90.00

Multiple myeloma not having achieved remission

C90.02

Multiple myeloma in relapse

C90.10

Plasma cell leukemia not having achieved remission

C90.12

Plasma cell leukemia in relapse

REIMBURSEMENT INFORMATION:

Refer to section entitled POSITION STATEMENT.

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Part D: BCBSF has delegated to Prime Therapeutics authority to make coverage determinations for the Medicare Part D services referenced in this guideline.

Medicare Advantage: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline review date.

DEFINITIONS:

Heavy chain – the larger component of an immunoglobulin. There are five types: IgG, IgA, IgM, IgD, and IgE.

Immunoglobulins (a.k.a., antibodies) proteins made by normal plasma cells that have an important role in fighting infection as part of the humoral immune response. Antibodies are composed of two heavy chains and two light chains that form a larger complex. Each plasma cell produces only one type of heavy chain and one type of light chain.

Light chain – the smaller component of an immunoglobulin. There are two types: kappa and lambda.

Minimal response (MR) (according to the Revised Uniform Response Criteria by the International Myeloma Working Group)ALL of the following:

• ≥25% but ≤49% reduction of serum M-protein

• Reduction in 24-hour urine M-protein by 50% to 89%

• In addition, if present at baseline, 25% to 49% reduction in size of soft tissue plasmacytomas is also required

• No increase in size or number of lytic bone lesions (development of compression fractures dose not exclude response).

Myeloma Protein (M-Protein) – a nonfunctional immunoglobulin protein or protein fragment produced by malignant plasma cells (or myeloma cells). Since myeloma cells are monoclonal, the M-proteins for a given patient are structurally identical. Both portions of an immunoglobulin (the heavy chain and light chain) can be found in the serum, while only light chains can be found in the urine.

Plasma cell - a fully differentiated B lymphocyte (a type of white blood cell) that is specialized for immunoglobulin production and is found primarily in bone marrow.

Primary refractory MM - patients who never achieve at least a MR to initial induction therapy and progress while on therapy

Progressive MM - at least a 25% increase from nadir in the serum M-protein (absolute increase must be ≥0.5 g/dL) or urine M-protein (absolute increase must be ≥200mg/24 hours), or in the difference between involved and uninvolved serum-free light-chain (FLC) levels (with an abnormal FLC ratio and FLC difference >100 mg/L).

Relapsed and refractory MM - patients who never achieve at least a MR or who progress within 60 days of their last therapy

Serum free light chain assay (SFLCA) – a test that detects the amount of unbound or free light chains (i.e., not attached to a heavy chain) in the serum. Normal values - kappa: 3.3 to 19.4 mg/L, lambda: 5.71 to 26.3 mg/L, kappa/lambda ratio: 0.26–1.65 (0.37–3.1 if renal impairment).

Serum Protein Electrophoresis (SPEP) – a test that detects and quantifies the amount of M-protein in the serum. An serum M-protein of greater than 30 g/L is consistent with a diagnosis of MM.

RELATED GUIDELINES:

Allogeneic Bone Marrow and Stem Cell Transplantation, 02-38240-01
Bortezomib (Velcade®) IV, 09-J0000-92

Carfilzomib (Kyprolis®) IV, 09-J1000-81

Doxorubicin HCl Liposome (Doxil®) IV, 09-J0000-91

Elotuzumab (Empliciti®) IV, 09-J2000

Ixazomib (Ninlaro), 09-J2000-51

Lenalidomide (Revlimid®), 09-J0000-80

Panobinostat (Farydak®), 09-J2000-37

Pomalidomide (Pomalyst®) Capsule, 09-J1000-95

Thalidomide (Thalomid®) Capsules, 09-J1000-56

OTHER:

None

REFERENCES:

  1. A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma. ClinicalTrials.gov Identifier: NCT01998971 Accessed June 23, 2017 at: https://clinicaltrials.gov/ct2/show/NCT01998971
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: www.clinicalpharmacilogy-ip.com. Accessed 5/25/17.
  3. Darzalex (daratumumab) injection [package insert]. Horsham, PA: Janssen Biotech, Inc. June 2017.
  4. Dimopoulos MA, Oriol A, Nahi H, et al.; POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331.
  5. FDA Orphan Drug Designations and Approvals [Internet]. Washington, D.C. [cited 2017 May 30]. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/.
  6. Lokhorst HM, Plesner T, and Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373(13):1207-1219.
  7. Micromedex® Healthcare Series [Internet Database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed 05/25/17.
  8. National Comprehensive Cancer Network. Cancer Guidelines. Cancer Guidelines and Drugs and Biologics Compendium. Accessed 06/23/17.
  9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Version 3.2017 Multiple Myeloma. Available at http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed 06/23/17.
  10. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the BCBSF Pharmacy Policy Committee on 06/14/17.

GUIDELINE UPDATE INFORMATION:

03/15/16

New Medical Coverage Guideline.

04/15/16

Revision to guideline consisting of clarifying the position statement.

07/01/16

Revision to guideline consisting of HCPCS code updates.

11/15/16

Revision to guideline consisting of updating the position statement, description section, and references based on new NCCN recommendations.

12/15/16

Revision to guideline consisting of updating the position statement with a new triplet regimen and updating the lab documentation requirements.

01/01/17

Revision to guideline consisting of updating the description section, dosage/administration, and references based on new FDA-approved indications. Added HCPCS code J9145.

02/16/17

Revision: Update to Position Statement.

07/15/17

Review and revision to guidelines consisting of updating the description section, position statement, and references.

09/15/17

Revision to guidelines consisting of updating the description section, position statement, dosage/administration section, and references based on new FDA-approved indication for use in combination with pomalidomide and dexamethasone.

Date Printed: October 17, 2017: 04:12 PM